FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

FDA evaluates ZINBRYTA for MS treatment

























The U.S. Food and Drug Administration (FDA) has announced it will consider marketing approval of ZINBRYTA (daclizumab high-yield process), a potential treatment for relapsing forms of multiple sclerosis (MS). Biogen and AbbVie, who are jointly developing the therapy, have filed a Biologics License Application (BLA) with the FDA in hopes of winning approval.

The two companies issued the request to the FDA along with data from two pivotal trials conducted to assess ZINBRYTA 150 mg (DECIDE and SELECT), during which investigators administered the treatment subcutaneously in patients with relapsing-remitting MS. Prior to this new filing, both companies had already been granted a Marketing Authorization Application for ZINBRYTA by the European Medicines Agency to be reviewed in the European Union.

“We are pleased by the FDA’s acceptance of our BLA for ZINBRYTA, which we believe has the potential to help people living with MS,” stated Gilmore O’Neill, the vice president for Multiple Sclerosis Research and Development at Biogen, in a press release. “We look forward to working with both U.S. and European regulatory authorities to bring this investigational treatment to MS patients as soon as possible.”

“This is an important milestone in the development program for ZINBRYTA and moves us a step closer to potentially bringing a new treatment option to patients with MS,” added the executive vice president for Research and Development and Chief Scientific Officer at AbbVie, Michael Severino, MD.

The investigational treatment ZINBRYTA is a novel form of a humanized monoclonal antibody that can target and connect to the high-affinity interleukin-2 (IL-2) receptor subunit (CD25). The subunit is present in T-cells in high levels in patients with MS, and the therapy is expected to influence natural killer (NK) cells that impact the immune system regulation.

Last September, the two companies were present at the 6th Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRMIS) to showcase the results of their phase 3 clinical trial on ZINBRYTA, demonstrating its effectiveness in relieving the symptoms experienced due to MS.

Patients saw a statistically significant reduction in disease activity when compared to patients treated with the established treatment, AVONEX (interferon beta-1a). This positive data was generated through the two- to three-year phase 3 study of more than 1,800 relapse-remitting multiple sclerosis patients from 28 countries. Patients were given either 150 mg subcutaneous ZINBRYTA every four weeks or 30 mcg intramuscular AVONEX once weekly.


Story Source: The above story is based on materials provided by 24HOURSVANCOUVER
Note: Materials may be edited for content and length


Go to Newer News Go to Older News